GAROFALO, MARIANGELA
 Distribuzione geografica
Continente #
NA - Nord America 3.189
AS - Asia 1.799
EU - Europa 1.126
AF - Africa 518
SA - Sud America 356
OC - Oceania 55
Continente sconosciuto - Info sul continente non disponibili 23
Totale 7.066
Nazione #
US - Stati Uniti d'America 2.951
SG - Singapore 669
CN - Cina 318
IT - Italia 271
BR - Brasile 214
HK - Hong Kong 165
VN - Vietnam 150
DE - Germania 89
PL - Polonia 65
FI - Finlandia 57
NL - Olanda 46
GB - Regno Unito 42
RU - Federazione Russa 40
FR - Francia 35
AR - Argentina 33
BJ - Benin 33
IR - Iran 30
ID - Indonesia 28
IE - Irlanda 28
AT - Austria 27
ES - Italia 25
KR - Corea 25
UA - Ucraina 24
SE - Svezia 22
IL - Israele 21
JO - Giordania 21
NZ - Nuova Zelanda 21
ET - Etiopia 20
DZ - Algeria 19
EC - Ecuador 19
GE - Georgia 19
GN - Guinea 19
LU - Lussemburgo 19
RO - Romania 19
ZA - Sudafrica 19
CH - Svizzera 18
EG - Egitto 18
IN - India 18
IQ - Iraq 18
PS - Palestinian Territory 18
GR - Grecia 17
ME - Montenegro 17
NO - Norvegia 17
BA - Bosnia-Erzegovina 16
CV - Capo Verde 16
EE - Estonia 16
JM - Giamaica 16
MA - Marocco 16
MR - Mauritania 16
NP - Nepal 16
UZ - Uzbekistan 16
ZM - Zambia 16
ZW - Zimbabwe 16
AO - Angola 15
BE - Belgio 15
DK - Danimarca 15
LB - Libano 15
MK - Macedonia 15
MW - Malawi 15
PT - Portogallo 15
SI - Slovenia 15
TR - Turchia 15
YT - Mayotte 15
AL - Albania 14
AZ - Azerbaigian 14
BB - Barbados 14
BO - Bolivia 14
CR - Costa Rica 14
CU - Cuba 14
GT - Guatemala 14
HN - Honduras 14
JP - Giappone 14
MD - Moldavia 14
PY - Paraguay 14
RS - Serbia 14
SN - Senegal 14
TW - Taiwan 14
UY - Uruguay 14
XK - ???statistics.table.value.countryCode.XK??? 14
AD - Andorra 13
AE - Emirati Arabi Uniti 13
AF - Afghanistan, Repubblica islamica di 13
BZ - Belize 13
CA - Canada 13
CI - Costa d'Avorio 13
CL - Cile 13
CO - Colombia 13
CY - Cipro 13
CZ - Repubblica Ceca 13
DJ - Gibuti 13
LV - Lettonia 13
ML - Mali 13
MX - Messico 13
NE - Niger 13
TJ - Tagikistan 13
GA - Gabon 12
HT - Haiti 12
LA - Repubblica Popolare Democratica del Laos 12
LC - Santa Lucia 12
LY - Libia 12
Totale 6.546
Città #
Fairfield 508
Ashburn 378
Singapore 317
Seattle 226
Woodbridge 211
Cambridge 177
Houston 171
Hong Kong 144
Wilmington 135
Chandler 116
Ann Arbor 89
Beijing 87
Padova 87
Santa Clara 85
Boardman 83
San Diego 55
Ho Chi Minh City 51
Medford 45
Princeton 45
Munich 41
Bytom 40
Chicago 39
Los Angeles 37
Hanoi 34
Cotonou 31
Hefei 31
Des Moines 28
Helsinki 27
Milan 26
Dong Ket 25
São Paulo 24
Dublin 23
Buffalo 19
Conakry 19
Amman 18
Nuremberg 17
Lappeenranta 16
Tbilisi 16
Warsaw 16
Addis Ababa 15
London 15
Lusaka 15
Podgorica 15
Seoul 15
Vienna 15
Baku 14
Havana 14
Jinan 14
Nouakchott 14
Tashkent 14
Bamako 13
Dakar 13
Dushanbe 13
Praia 13
Stockholm 13
Abidjan 12
Andorra la Vella 12
Athens 12
Bridgetown 12
Castries 12
Harare 12
Lilongwe 12
Montevideo 12
Panama City 12
Redondo Beach 12
Rio de Janeiro 12
Shenyang 12
Vientiane 12
Auckland 11
Libreville 11
Ljubljana 11
Luanda 11
Luxembourg 11
Roxbury 11
Salt Lake City 11
Tallinn 11
Bishkek 10
Dar es Salaam 10
Djibouti 10
New York 10
Niamey 10
Padua 10
Phnom Penh 10
San José 10
Belize City 9
Guatemala City 9
Kampala 9
Limassol 9
Managua 9
Nairobi 9
Nanjing 9
San Francisco 9
Tripoli 9
Turku 9
Ulan Bator 9
Willemstad 9
Algiers 8
Cairo 8
Fort Liberté 8
Kingston 8
Totale 4.226
Nome #
Physical PEGylation to Prevent Insulin Fibrillation 201
Dexamethasone loaded liposomes by thin‐film hydration and microfluidic procedures: Formulation challenges 165
Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model 161
Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment 157
Thermosensitive "Smart" Surfaces for Biorecognition Based Cell Adhesion and Controlled Detachment 151
Extracellular vesicles powered cancer immunotherapy: Targeted delivery of adenovirus-based cancer vaccine in humanized melanoma model 146
408. Oncolytic Vaccines in Combination with PD-L1 Blockade for the Treatment of Melanoma 146
Oncolytic adenovirus loaded with L-carnosine as novel strategy to enhance the antitumor activity 143
From Immunosuppression to Immunomodulation – Turning Cold Tumours into Hot 142
Cancer vaccines: an update on recent achievements and prospects for cancer therapy 141
Heterologous and cross-species tropism of cancer-derived extracellular vesicles 140
Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma 140
Polymer coated oncolytic adenovirus to selectively target hepatocellular carcinoma cells 138
The evolution of adenoviral vectors through genetic and chemical surface modifications 135
Glabrescione B delivery by self-assembling micelles efficiently inhibits tumor growth in preclinical models of Hedgehog-dependent medulloblastoma 134
Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity 133
Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer 133
A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma 130
220. Evaluation of the Efficacy of a New Oncolytic Vaccine Platform in Humanized Mice 130
Extracellular vesicles enhance the targeted delivery of immunogenic oncolytic adenovirus and paclitaxel in immunocompetent mice. 130
Systemic Administration and Targeted Delivery of Immunogenic Oncolytic Adenovirus Encapsulated in Extracellular Vesicles for Cancer Therapies 129
661. Synergistic Anti-Tumor Efficacy of Immunogenic Adenovirus ONCOS-102 and Standard of Care Chemotherapy in Preclinical Mesothelioma Model 124
71. Boosting the Immunogenicity of an Oncolytic Vaccinia Virus By Expression of DAI Can Enhance Anti-Tumor Immunity in Humanized Mice 124
PEG-polyaminoacid based micelles for controlled release of doxorubicin: Rational design, safety and efficacy study 124
The Anti-Proliferative Effect of L-Carnosine Correlates with a Decreased Expression of Hypoxia Inducible Factor 1 alpha in Human Colon Cancer Cells 123
Optimization of Early Steps in Oncolytic Adenovirus ONCOS-401 Production in T-175 and HYPERFlasks 123
Cancer-derived EVs show tropism for tissues at early stage of neoplastic transformation 121
Combination Therapy of Novel Oncolytic Adenovirus with Anti-PD1 Resulted in Enhanced Anti-Cancer Effect in Syngeneic Immunocompetent Melanoma Mouse Model 120
Priming with oncolytic adenovirus followed by anti-PD-1 and paclitaxel treatment leads to improved anti-cancer efficacy in the 3D TNBC model 119
Screening of chemical linkers for development of pullulan bioconjugates for intravitreal ocular applications 119
PCSK9 promotes arterial medial calcification 119
Development of nanovehicles for co-delivery of colistin and ArnT inhibitors 114
Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model 114
622. Oncolytic Adenoviruses Loaded With Active Drugs as a Novel Drug Delivery System for Cancer Therapy 114
Oncolytic adenoviruses coated with MHC-I tumor epitopes for a new oncolytic vaccine platform 112
From Conventional Therapies to Immunotherapy: Melanoma Treatment in Review 112
Isoflavones in aglycone solution enhance ultraviolet B-induced DNA damage repair efficiency 109
Inhibition of SIRT1 deacetylase and p53 activation uncouples the anti-inflammatory and chemopreventive actions of NSAIDs 108
Transplantation of autologous extracellular vesicles for cancer-specific targeting 108
Oncolytic adenovirus loaded with L-carnosine as a drug delivery system for cancer therapy 103
Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects 101
How Computational Chemistry and Drug Delivery Techniques Can Support the Development of New Anticancer Drugs 101
Focused Design of Novel Cyclic Peptides Endowed with GABARAP-Inhibiting Activity 100
L-Carnosine and Human Colon Cancer 99
Enhancing the activity of γ-hydroxy lactone derivatives as innovative peroxisome proliferator-activated receptor γ non-agonists inhibiting cyclin-dependent kinase 5-mediated phosphorylation 98
Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2 93
Erratum: The anti-proliferative effect of L-carnosine correlates with a decreased expression of hypoxia inducible factor 1 alpha in human colon cancer cells (PLoS ONE (2014) 9, 5 (e96755) DOI: 10.1371/journal.pone.0096755) 93
Computational Design of Novel Cyclic Peptides Endowed with Autophagy-Inhibiting Activity on Cancer Cell Lines 89
The Multifaceted Roles of Mast Cells in Immune Homeostasis, Infections and Cancers 88
MUG Mel3 Cell Lines Reflect Heterogeneity in Melanoma and Represent a Robust Model for Melanoma in Pregnancy 85
Structural basis for specific inhibition of salicylate synthase from Mycobacterium abscessus 84
Novel combinatorial therapy of oncolytic adenovirus AdV5/3-D24-ICOSL-CD40L with anti PD-1 exhibits enhanced anti-cancer efficacy through promotion of intratumoral T-cell infiltration and modulation of tumour microenvironment in mesothelioma mouse model 84
Oncolytic Adenovirus-Based Immunotherapy for Malignant Mesothelioma: Preclinical Advances and Future Perspectives 75
Application of array-CGH analysis in immune-virotherapy approach 74
Molecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review 72
Induction of an immune response by a nonreplicating adenoviruses-based formulation versus a commercial pseudo-SARS-CoV-2 vaccine 72
null 66
In vitro immune evaluation of adenoviral vector-based platform for infectious diseases 62
I Vaccini 62
L-Carnosine inhibits KRAS-mediated HCT116 proliferation, by affecting ROS production and Hypoxia inducible factor (HIF-1) expression 59
Unlocking the potential of microfluidic assisted formulation of exenatide-loaded solid lipid nanoparticles 55
Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model 53
Oncologia 52
Localized treatment of glioblastoma: a review of clinical strategies and advances in drug delivery systems 47
Doxorubicin liposomes cell penetration enhancement and its potential drawbacks for the tumor targeting efficiency 34
Development of an in vitro method to assess the immunogenicity of biologics in the prevention of infectious diseases 23
Dynamic 3D microfluidic platform for exploring combined targeted therapy, chemotherapy, and virotherapy delivery in ovarian cancer 10
Totale 7.166
Categoria #
all - tutte 23.358
article - articoli 22.454
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 720
Totale 46.532


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021448 0 0 0 0 0 16 69 82 82 70 86 43
2021/2022663 13 37 76 60 59 27 27 134 80 13 22 115
2022/2023335 73 1 4 23 70 46 1 38 46 3 15 15
2023/2024254 10 44 38 19 9 10 18 17 8 6 46 29
2024/20251.152 9 44 41 51 130 55 71 90 89 49 194 329
2025/20263.181 322 461 926 1.003 464 5 0 0 0 0 0 0
Totale 7.166